Portions of this exhibit marked [*] are requested to be treated confidentially. COLLABORATIVE RESEARCH AND DEVELOPMENT AND LICENSE AGREEMENTCollaborative Research and Development and License Agreement • October 12th, 2011 • Cempra Holdings, LLC • North Carolina
THIS COLLABORATIVE RESEARCH AND DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is entered into as of March 31, 2006 (the “Effective Date”) by and between OPTIMER PHARMACEUTICALS INC., a Delaware corporation with its offices located at 10110 Sorrento Valley Road, Suite C, San Diego, California 92121 (“Optimer”), and CEMPRA PHARMACEUTICALS, INC., a Delaware corporation with its offices located at 170 Southport Drive, Suite 500, Morrisville, NC 27560. Optimer and Cempra may be referred to herein individually as a “Party” or collectively, as the “Parties.”
AMENDED AND RESTATED COLLABORATIVE RESEARCH AND DEVELOPMENT AND LICENSE AGREEMENTCollaborative Research and Development and License Agreement • April 28th, 2004 • Metabasis Therapeutics Inc • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED COLLABORATIVE RESEARCH AND DEVELOPMENT AND LICENSE AGREEMENT (this "Agreement"), dated as of June 30, 1999, is between METABASIS THERAPEUTICS, INC., a Delaware corporation having its principal place of business at 9390 Towne Centre Drive, San Diego, California 92121 ("MTI"), and SANKYO CO., LTD., a Japanese corporation having its principal place of business at 5-1 Nihonbashi-Honcho, 3-chome, Chuo-ku, Tokyo 103, Japan ("Sankyo").
Confidential Treatment Requested. Confidential Portions of this Agreement have been redacted and have been separately filed with the Commission.]Collaborative Research and Development and License Agreement • November 14th, 2000 • Nanogen Inc • Laboratory analytical instruments
COLLABORATIVE RESEARCH AND DEVELOPMENT AND LICENSE AGREEMENTCollaborative Research and Development and License Agreement • March 12th, 2009 • Optimer Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS COLLABORATIVE RESEARCH AND DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is entered into as of March 31, 2006 (the “Effective Date”) by and between OPTIMER PHARMACEUTICALS INC., a Delaware corporation with its offices located at 10110 Sorrento Valley Road, Suite C, San Diego, California 92121 (“Optimer”), and CEMPRA PHARMACEUTICALS, INC., a Delaware corporation with its offices located at 170 Southport Drive, Suite 500, Morrisville, NC 27560. Optimer and Cempra may be referred to herein individually as a “Party” or collectively, as the “Parties.”
